Literature DB >> 32700628

Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.

Yongzhen Chen1, Fang Fang2, Kelley M Kidwell2,3, Kiran Vangipuram4, Lauren A Marcath5, Christina L Gersch3,6, James M Rae3,6, Daniel F Hayes3,6, Ellen M Lavoie Smith7, N Lynn Henry3,8, Andreas S Beutler9,10, Daniel L Hertz3,4.   

Abstract

Aim: This study explored whether inherited variants in genes causing the hereditary neuropathy condition Charcot-Marie-Tooth disease are associated with sensitivity to paclitaxel-induced peripheral neuropathy (PN). Patients & methods: Hereditary neuropathy genes previously associated with risk of paclitaxel-induced PN were sequenced in paclitaxel-treated patients. Eight putative genetic predictors in five hereditary neuropathy genes (ARHGEF10, SBF2, FGD4, FZD3 and NXN) were tested for association with PN sensitivity after accounting for systemic exposure and clinical variables.
Results: FZD3 rs7833751, a proxy for rs7001034, decreased PN sensitivity (additive model, β = -0.41; 95% CI: -0.66 to -0.17; p = 0.0011). None of the other genetic predictors were associated with PN sensitivity.
Conclusion: Our results support prior evidence that FZD3 rs7001034 is protective of PN and may be useful for individualizing paclitaxel treatment to prevent PN.

Entities:  

Keywords:  ARHGEF10; FZD3; paclitaxel; peripheral neuropathy; pharmacogenomics

Mesh:

Substances:

Year:  2020        PMID: 32700628      PMCID: PMC7444626          DOI: 10.2217/pgs-2020-0053

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  46 in total

Review 1.  Grading of chemotherapy-induced peripheral neuropathy.

Authors:  T J Postma; J J Heimans
Journal:  Ann Oncol       Date:  2000-05       Impact factor: 32.976

Review 2.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

Review 3.  Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.

Authors:  Stephan Mielke; Alex Sparreboom; Klaus Mross
Journal:  Eur J Cancer       Date:  2005-11-15       Impact factor: 9.162

4.  Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Authors:  Lara E Sucheston-Campbell; Alyssa I Clay-Gilmour; William E Barlow; G Thomas Budd; Daniel O Stram; Christopher A Haiman; Xin Sheng; Li Yan; Gary Zirpoli; Song Yao; Chen Jiang; Kouros Owzar; Dawn Hershman; Kathy S Albain; Daniel F Hayes; Halle C Moore; Timothy J Hobday; James A Stewart; Abbas Rizvi; Claudine Isaacs; Muhammad Salim; Jule R Gralow; Gabriel N Hortobagyi; Robert B Livingston; Deanna L Kroetz; Christine B Ambrosone
Journal:  Pharmacogenet Genomics       Date:  2018-02       Impact factor: 2.089

5.  Transcriptional profiling of the injured sciatic nerve of mice carrying the Wld(S) mutant gene: identification of genes involved in neuroprotection, neuroinflammation, and nerve regeneration.

Authors:  Benoit Barrette; Ezéquiel Calvo; Nicolas Vallières; Steve Lacroix
Journal:  Brain Behav Immun       Date:  2010-08-03       Impact factor: 7.217

Review 6.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

7.  Identification of a negative regulatory region for the exchange activity and characterization of T332I mutant of Rho guanine nucleotide exchange factor 10 (ARHGEF10).

Authors:  Taro Chaya; Satoshi Shibata; Yasunori Tokuhara; Wataru Yamaguchi; Hiroshi Matsumoto; Ichiro Kawahara; Mikihiko Kogo; Yoshiharu Ohoka; Shinobu Inagaki
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

8.  Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.

Authors:  Andreas S Beutler; Amit A Kulkarni; Rahul Kanwar; Christopher J Klein; Terry M Therneau; Rui Qin; Michaela S Banck; Ganesh K Boora; Kathryn J Ruddy; Yanhong Wu; Regenia L Smalley; Julie M Cunningham; Nguyet Anh Le-Lindqwister; Peter Beyerlein; Gary P Schroth; Anthony J Windebank; Stephan Züchner; Charles L Loprinzi
Journal:  Ann Neurol       Date:  2014-09-17       Impact factor: 10.422

9.  Predicting the functional effect of amino acid substitutions and indels.

Authors:  Yongwook Choi; Gregory E Sims; Sean Murphy; Jason R Miller; Agnes P Chan
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

10.  A general framework for estimating the relative pathogenicity of human genetic variants.

Authors:  Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

View more
  4 in total

Review 1.  Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.

Authors:  Katherina C Chua; Nura El-Haj; Josefina Priotti; Deanna L Kroetz
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-10-02       Impact factor: 4.080

Review 2.  Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.

Authors:  Daniel L Hertz
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-06       Impact factor: 4.481

Review 3.  Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions.

Authors:  Rozalyn L Rodwin; Namrah Z Siddiq; Barbara E Ehrlich; Maryam B Lustberg
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-14

4.  A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.

Authors:  Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.